Firefly Neuroscience (NASDAQ:AIFF – Get Free Report) and Nutanix (NASDAQ:NTNX – Get Free Report) are both business services companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Firefly Neuroscience and Nutanix, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Firefly Neuroscience | 0 | 0 | 0 | 0 | 0.00 |
Nutanix | 0 | 3 | 12 | 0 | 2.80 |
Nutanix has a consensus target price of $79.50, indicating a potential upside of 13.12%. Given Nutanix’s stronger consensus rating and higher probable upside, analysts clearly believe Nutanix is more favorable than Firefly Neuroscience.
Risk and Volatility
Valuation & Earnings
This table compares Firefly Neuroscience and Nutanix”s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Firefly Neuroscience | $7.98 million | 12.92 | -$2.03 million | N/A | N/A |
Nutanix | $2.15 billion | 8.76 | -$124.78 million | ($0.35) | -200.80 |
Firefly Neuroscience has higher earnings, but lower revenue than Nutanix.
Insider & Institutional Ownership
5.0% of Firefly Neuroscience shares are held by institutional investors. Comparatively, 85.3% of Nutanix shares are held by institutional investors. 8.4% of Firefly Neuroscience shares are held by insiders. Comparatively, 6.8% of Nutanix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Firefly Neuroscience and Nutanix’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Firefly Neuroscience | -73.72% | -276.50% | -133.02% |
Nutanix | -3.54% | -12.28% | 3.30% |
Summary
Nutanix beats Firefly Neuroscience on 8 of the 12 factors compared between the two stocks.
About Firefly Neuroscience
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.
About Nutanix
Nutanix, Inc. engages in the provision of a cloud platform leveraging web-scale engineering and consumer-grade design. It operates through the following geographic segments: United States, Europe, the Middle East, Africa, Asia Pacific, and Other Americas. The firm also provides software solutions and cloud services to customers’ enterprise infrastructure. The company was founded by Dheeraj Pandey, Ajeet Singh, and Mohit Aron in 2009 and is headquartered in San Jose, CA.
Receive News & Ratings for Firefly Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Firefly Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.